Follistatin-344: what the research shows
- By Reed Calder
- Last reviewed Nov 13, 2026
- 29 studies and official documents checked
In short
Follistatin-344 is a protein, not a short peptide. The body makes follistatin as a 344-amino-acid chain that is trimmed to 315 amino acids, about 38,000 daltons, and it binds myostatin and activin, two signals that limit muscle size. Extra follistatin built muscle in mice, monkeys and pigs. In people, the follistatin-344 studies used gene therapy injected into the thigh muscles: 6 men with Becker muscular dystrophy, and 6 people with inclusion body myositis, a result a published letter disputed. A follistatin-based drug, ACE-083, raised muscle volume in randomized trials without consistent gains in function, and both muscle-disease programs were stopped. We found no trial of injected follistatin protein in people. Tests of vials sold as follistatin-344 found follistatin in 9 of 17, and 11 bodybuilders developed fluid under the retina after injecting it. It isn’t FDA-approved, and the World Anti-Doping Agency bans it.
EvidenceCellAnimalHumanhuman data come from gene therapy and a related drug, not injected follistatin
You’ll often read that follistatin-344 is a peptide that blocks myostatin to build muscle without training, lasts about 35 hours, repairs tissue and joints, grows hair and is well tolerated. This page covers what it is, what each study used, what happened in the human trials, what testing of vials sold online found, its side effects, and where it stands legally.
Names and forms you’ll see
| Name | What it is | Studied in people? |
|---|---|---|
| Follistatin, FST | A protein the body makes that binds activin and myostatin. The FST gene encodes a 344-amino-acid precursor (UniProt P19883) | Blood levels measured; not given as a protein |
| Follistatin-344, FS344 | The 344-amino-acid form. After a 29-amino-acid lead piece is removed, the circulating protein has 315 amino acids, which gene-therapy papers call FS315 (UniProt P19883; Al-Zaidy et al., 2015) | Only as gene therapy |
| Follistatin-288, FS288 | A shorter form that sticks to cell surfaces and binds activin about 10 times more tightly than FS344 (Al-Zaidy et al., 2015) | No study found |
| AAV1.CMV.FS344 | The gene-therapy product: a harmless virus carrying the FS344 gene, injected into muscle so the muscle makes the protein (Mendell et al., 2015) | Yes: the trials below |
| ACE-083 | A follistatin-based fusion protein drug made by Acceleron, injected into single muscles (Pearsall et al., 2019) | Yes: three trials below |
| Follistatin plasmid gene therapy | A ring of DNA carrying the follistatin gene, registered by a longevity company (NCT06411366) | Registered; we found no results |
| Follistatin-like proteins (FSTL1, FSTL3) | Different proteins with similar names; not this page | Not this page |
| Vials sold online as “follistatin 344 peptide” | Products sold as injections. In one lab test, only 9 of 17 contained follistatin (Reichel et al., 2019) | No study of the injected product found |
CAS numbers
A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. The FDA’s registry lists follistatin by its UNII and its UniProt sequence entry, and gives no CAS number.
| Form | CAS number | Registry record |
|---|---|---|
| Follistatin (FST) | None listed | FDA GSRS |
What follistatin-344 is
Follistatin is a protein the body makes. It binds activin and myostatin, which are signals in the TGF-beta family, and keeps them from reaching their receptors. Myostatin limits how much muscle the body builds, which is why follistatin was tried as a muscle drug (Lee and McPherron, 2001).
The name “344” is the length of the chain the FST gene encodes. The first 29 amino acids are a lead piece that is cut off, leaving a mature protein of 315 amino acids and a mass near 38,000 daltons (UniProt P19883). That is a protein, not a peptide: the FDA treats a chain of more than 40 amino acids as a protein (21 CFR 600.3).
The gene-therapy team chose the FS344 form on purpose, because the circulating form avoids the cell-surface sites and the hormone effects of the shorter form, which can suppress FSH in the pituitary (Rodino-Klapac et al., 2009; Al-Zaidy et al., 2015).
As a drug, plain follistatin has a problem: drug developers describe fast clearance by the liver, which they traced to its heparin-binding loop and engineered away in mouse studies (Shen et al., 2018). We found no half-life measured for injected follistatin-344 in people.
What has been studied
In animals
| Study | Animal | What was used | What it found |
|---|---|---|---|
| Lee and McPherron, 2001 | Mice bred to make extra follistatin in muscle | A muscle-specific gene, so the animals made it for life | Dramatic increases in muscle mass, similar to mice with no myostatin |
| Haidet et al., 2008 | Normal and dystrophic mice | One gene delivery of follistatin or other myostatin inhibitors | Muscle mass and strength rose for more than 2 years, even in aged mice |
| Kota et al., 2009 | Cynomolgus macaque monkeys | AAV1-FS344 gene injected into a thigh muscle | Muscle size and strength rose and stayed up. Long-term expression caused no abnormal change in key organs. The authors report a provisional patent on follistatin gene delivery |
| Chang et al., 2017 | Transgenic pigs | Human follistatin-344 made in muscle | Lean meat was 72.95% against 69.18% in normal pigs (N = 16, p < 0.05). No heart enlargement or reproductive abnormality was seen |
EvidenceCellAnimalHumanmice, monkeys and pigs, all with the gene delivered, not injected protein
In people: gene therapy
Gene therapy is not the same as an injection of the protein. The virus makes follistatin inside muscle cells, continuously, for as long as the gene stays active. All the human follistatin-344 studies below delivered the gene.
| Study | Who | What was used | What it found |
|---|---|---|---|
| Mendell et al., 2015 (NCT01519349) | 6 men with Becker muscular dystrophy; open label, no comparison group | AAV1.CMV.FS344 into both thigh muscles in one session: 3 × 1011 vector genomes per kg per leg in 3 men, 6 × 1011 in 3 | The six-minute walk improved by 58, 125, 108 and 29 meters in four men and didn’t change in two. No adverse effects were reported. Biopsies showed less scarring and larger fibers, mainly at the higher amount |
| Mendell et al., 2017 | 6 people with sporadic inclusion body myositis, compared with 8 untreated people matched on age, sex and baseline; not randomized | The same gene, 6 × 1011 vector genomes per kg per leg, with an exercise regimen | Walk distance rose a median 56.0 meters a year in the treated and fell 25.8 meters a year in the untreated (p = 0.01). Four of six gained 58 to 153 meters; two gained 5 to 23. A letter argued the claim was unfounded, and the issue carries a reply (Greenberg, 2017; Europe PMC record) |
| NCT02354781 | 3 people with Duchenne muscular dystrophy (registry record with results); open label | 2.4 × 1012 vector genomes per kg in total, 1.2 × 1012 per limb | No dose-limiting toxicity. One serious event, a head injury from a fall. The record reports safety, not efficacy |
Other follistatin gene-therapy trials are registered by companies, including a plasmid trial in 43 people with frailty and aging, a second in 14 healthy adults, and a recruiting trial of an AAV9 follistatin gene with a VEGF plasmid for age-related muscle decline (NCT06411366; NCT07285629; NCT07443826). We found no published results for any of them.
EvidenceCellAnimalHuman12 people in two small open-label trials; one result disputed
In people: a follistatin-based drug, ACE-083
| Study | Who | What was used | What it found |
|---|---|---|---|
| Glasser et al., 2018 | 58 healthy postmenopausal women; double-blind, placebo-controlled | ACE-083, 50 to 200 mg into one muscle, once or twice 3 weeks apart | Muscle volume rose by up to 14.5% in a thigh muscle and 8.9% in a shin muscle. No significant change in strength. No serious events |
| Statland et al., 2022 (NCT02927080) | Adults with facioscapulohumeral muscular dystrophy: 37 in an open-label part, 58 in a randomized, double-blind part | 240 mg per muscle into the biceps or the shin muscle every 3 weeks, or placebo, for 6 months | Muscle volume rose 16.4% in the biceps and 9.5% in the shin muscle against placebo, with no consistent gains in function or patient-reported measures. The sponsor stopped the study because the functional endpoints weren’t met |
| Thomas et al., 2022 (NCT03124459) | 63 adults with Charcot-Marie-Tooth disease: 18 open label, 45 in a randomized part | 240 mg per muscle into the shin muscle, or placebo, for 6 months | Muscle volume rose 13.5 percentage points more than on placebo and ankle strength improved, but fat fraction and every other functional measure didn’t. The sponsor stopped the program for the same reason |
ACE-083 is a different product from follistatin-344, injected into one muscle at a time, and the muscle-disease trials were run by its maker, Acceleron, a Merck subsidiary (NCT03943290). Growing a muscle isn’t the same as improving what it can do.
EvidenceCellAnimalHumanmuscle volume rose, function didn’t, and both muscle-disease programs were stopped
Follistatin-344 as sold online
| Study | Who | What was used | What it found |
|---|---|---|---|
| Reichel et al., 2019; Reichel et al., 2020 erratum | 17 products sold as “follistatin 344” or “follistatin 315”, tested in a doping-control lab | Protein gels and blotting to look for follistatin | Only 9 of 17 contained follistatin. Some of the others held growth-promoting peptides such as MGF and GHRP-2. All nine follistatin products held His-tagged FS344 and many clumped copies, a lab-made version that can be told apart from the body’s own protein. The 2020 erratum corrected table columns |
| Dağ et al., 2020 | 11 male bodybuilders, average age 36.8, seen at one eye clinic | High-dose follistatin-344 injected under the skin of the abdomen; each had injected a whole vial | All 11 had central serous chorioretinopathy, fluid under the retina. In the 8 who had injected once it cleared in about 2.3 months; it returned in 3 who had injected more than once. A retrospective case series |
EvidenceCellAnimalHumanno controlled study of injected follistatin; a case series and product testing only
Hair and other uses
The one human hair study we found tested a cell-derived mix that contained follistatin, Wnt, KGF and VEGF, given as a single injection into the scalp skin of 26 people with pattern baldness. Hair thickness and density beat placebo at 12 weeks (Zimber et al., 2011). It wasn’t follistatin-344, and we found no study of follistatin-344 for hair, joints, the gut or tissue repair.
Who ran the studies
- The inventors. The gene-therapy trials came from the team that developed the approach, and the monkey paper reports a provisional patent on follistatin gene delivery (Kota et al., 2009; Mendell et al., 2015).
- A company. The ACE-083 trials were run by Acceleron and are reported with its staff as authors or advisers (Statland et al., 2022; Pearsall et al., 2019).
- Testing labs. The product-testing papers come from anti-doping laboratories, not from sellers (Reichel et al., 2019).
The usual claims, checked
| Claim | Verdict | What the studies found |
|---|---|---|
| Follistatin-344 is a peptide | Contradicted | No. Its mature form is 315 amino acids, and the FDA treats anything over 40 amino acids as a protein (UniProt P19883; 21 CFR 600.3) |
| It builds muscle in people | Mixed | Gene therapy gave mixed results in 6 men and 6 people, and a follistatin-based drug raised muscle volume without consistent gains in function (Mendell et al., 2015; Statland et al., 2022). We found no trial of injected follistatin protein in people |
| It makes muscle growth permanent | Untested | In mice, one gene delivery kept muscle larger for more than 2 years (Haidet et al., 2008). That was a gene making the protein continuously, not an injection. We found no study of injected protein in any animal or person |
| It treats muscular dystrophy | Mixed | In 6 men with Becker muscular dystrophy given the gene, 4 walked farther and 2 didn’t, with no comparison group (Mendell et al., 2015). The FDA has approved no follistatin product for any disease |
| It treats inclusion body myositis | Mixed | Six people given the gene walked farther than 8 matched, untreated people, in a non-randomized comparison that a published letter said couldn’t support the claim (Mendell et al., 2017; Greenberg, 2017) |
| Injecting the vial works like the gene therapy | Untested | Gene therapy makes the protein inside muscle; a vial supplies it from outside, and drug developers describe fast clearance of follistatin by the liver (Shen et al., 2018). We found no study of the injected protein in people |
| It lasts about 35 hours | Untested | We found no source for that figure and no half-life measured in people. Mouse work found follistatin cleared quickly unless its heparin-binding loop was changed (Shen et al., 2018) |
| It is well tolerated and safe | Mixed | The gene-therapy trials reported no adverse effects in 6 men and no dose-limiting toxicity in 3 people (Mendell et al., 2015; NCT02354781). But 11 men developed fluid under the retina after injecting follistatin-344 (Dağ et al., 2020), and no study has tested injected follistatin for safety |
| It repairs tissue and helps joints, gut and hair | Untested | We found no study of follistatin-344 for any of these. The one human hair study used a cell-derived mix of several factors, not follistatin-344 (Zimber et al., 2011) |
| Vials sold as follistatin 344 contain follistatin 344 | Mixed | Only 9 of 17 tested products contained follistatin, and all nine held a His-tagged lab version; others held different growth peptides (Reichel et al., 2019) |
| The microgram doses sold online come from research | Untested | No study gave a person an injected follistatin protein, so no such dose comes from a study. Gene-therapy amounts are counted in virus particles, not micrograms (Mendell et al., 2015) |
| It is FDA-approved | Contradicted | No. The FDA’s approved-drug data return no product under the name follistatin (openFDA Drugs@FDA), and gene therapy with it is still being tested in trials (NCT01519349) |
| Pharmacies can legally compound it | Contradicted | It is a protein of 315 amino acids, a different category from the short peptides the FDA has reviewed for compounding. We found no FDA listing for it, and it isn’t among the six peptides in the October 2026 HHS policy (FDA rule, 2020; Reuters, 2026) |
| It is banned in sport | Supported | Yes. The World Anti-Doping Agency’s 2026 list names follistatin among myostatin-binding proteins prohibited at all times (WADA, 2026) |
Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.
What the studies used
| Study | What was tested | Amount and route |
|---|---|---|
| Mendell et al., 2015 | Becker muscular dystrophy | FS344 gene by AAV1 into both thigh muscles: 3 × 1011 or 6 × 1011 vector genomes per kg per leg, one session |
| Mendell et al., 2017 | Inclusion body myositis | 6 × 1011 vector genomes per kg per leg, with an exercise regimen |
| NCT02354781 | Duchenne muscular dystrophy | 2.4 × 1012 vector genomes per kg in total, into the limbs |
| Glasser et al., 2018 | ACE-083 in healthy women | 50 to 200 mg into one muscle, 1 or 2 doses 3 weeks apart |
| Statland et al., 2022; Thomas et al., 2022 | ACE-083 in muscle disease | 240 mg per muscle every 3 weeks, for up to 9 doses (NCT03124459) |
| Dağ et al., 2020 | Injected follistatin-344, as reported by users | A whole vial under the skin of the abdomen, described by the authors as high dose; the amount isn’t in the abstract |
Gene-therapy amounts count virus particles and can’t be turned into micrograms of protein, and ACE-083 is a different drug. No study tested an injected follistatin-344 protein in a person, so there is no study amount for it. These are amounts from studies, not advice for anyone to use.
Side effects and safety
- Eye. Eleven bodybuilders developed central serous chorioretinopathy, a build-up of fluid under the retina, after high-dose follistatin-344 injections. It cleared in about 2.3 months in the 8 who injected once and came back in the 3 who injected more than once. The authors say injections can be considered a risk factor (Dağ et al., 2020).
- Gene therapy. The Becker trial reported no adverse effects, and the Duchenne record lists no dose-limiting toxicity and one serious event, a head injury from a fall (Mendell et al., 2015; NCT02354781). Monkeys given the gene showed no abnormal organ changes (Kota et al., 2009).
- ACE-083. In its trials, injection-site reactions were the most common side effect, and serious events were rare (Thomas et al., 2022; Statland et al., 2022). It is a different drug, injected into one muscle.
- Hormones. Follistatin can suppress FSH in the pituitary, which is why the gene-therapy team chose the form that avoids cell-surface sites (Al-Zaidy et al., 2015). The pigs made to produce it showed no reproductive abnormality (Chang et al., 2017). We found no human study of reproductive hormones after injected follistatin.
- Not safety-tested. No study has tested injected follistatin-344 for safety. A 2026 sports-medicine review of unapproved peptides, including follistatin-344, says rigorous human safety data are scarce (Mendias and Awan, 2026).
- What is in the vial. Only 9 of 17 tested products contained follistatin, and some held other growth-promoting peptides (Reichel et al., 2019).
- Not known. Long-term use, effects on cancer risk, immune reactions to a protein made in bacteria, pregnancy, and mixing with other drugs. Side effects people report from online products aren’t covered here; they come from users, not studies.
Legal and approval status
- Not FDA-approved. The FDA’s approved-drug data return no product under the name follistatin (openFDA Drugs@FDA).
- A protein, not a peptide. By FDA rule a protein is a chain of more than 40 amino acids with a defined sequence, and the law’s definition of a biological product includes proteins (FDA rule, 2020). Follistatin’s circulating form has 315 (UniProt P19883), so it isn’t one of the short peptides the FDA has reviewed for compounding. We found no FDA listing for it: neither FDA’s lists of nominated bulk substances nor its safety-risk page names follistatin (FDA category list, 2026; FDA, 2026).
- Gene therapy is investigational. The follistatin gene-therapy trials above were run under trial rules, not as approved treatment (NCT01519349).
- Not in the HHS policy. The October 2026 temporary policy covers six other peptides (Reuters, 2026).
- No trial of injected protein. ClinicalTrials.gov lists no study of injected follistatin protein; its follistatin records are gene therapy, a related drug, or blood-level studies (ClinicalTrials.gov search).
- Research-use vials. Products labeled “research use only” aren’t approved for use in people.
- Sport. The World Anti-Doping Agency’s 2026 list names follistatin among myostatin-binding proteins in class S4, prohibited at all times (WADA, 2026).
What to look for if you research it
We don’t name or link sellers. These checks come from the studies and the FDA’s rules:
- Gene therapy or injection. Every human result for follistatin-344 is from gene therapy. A page that cites those results for an injected vial is borrowing evidence from a different product.
- “Peptide” isn’t accurate. It is a 315-amino-acid protein. Pages that call it a short peptide may be using a template for other products.
- The disputed result. The inclusion body myositis gain came from a non-randomized comparison of 6 and 8 people, and a published letter challenged it.
- Muscle size isn’t function. ACE-083 grew muscles in every trial and still didn’t improve function consistently.
- Unsourced numbers. A half-life of 35 hours, a list of benefits for joints and gut, or a dose table has no study behind it that we could find.
- What the vial holds. A lab found follistatin in 9 of 17 products, and those held His-tagged lab protein. A certificate of analysis from the seller isn’t an independent test.
- Missing safety. A page that calls it well tolerated without the eye case series has left out the one human safety report on injected follistatin-344.
Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite.
What’s still unknown
- Whether an injected follistatin-344 protein builds muscle in any person.
- How long injected follistatin lasts in the body, and how much reaches muscle.
- Whether the inclusion body myositis gain would hold up in a randomized trial.
- Whether follistatin gene therapy is safe over many years; the longest follow-up we found is the 2012 to 2017 trial window.
- What the eye finding means: how often it happens, and whether stopping reverses it.
- Whether injected follistatin affects the reproductive hormones.
- What is in vials sold online beyond one 2019 test of 17 products.
Retracted and flagged studies
A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.
We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention Follistatin-344. We recheck every month. Last checked Nov 13, 2026.
We found no retracted, withdrawn or flagged studies that mention Follistatin-344.
Studies this page relies on
| Study | Published in | Status |
|---|---|---|
| Lee and McPherron, 2001 | Proc Natl Acad Sci U S A | No retraction or concern |
| Haidet et al., 2008 | Proc Natl Acad Sci U S A | No retraction or concern |
| Rodino-Klapac et al., 2009 | Muscle Nerve | No retraction or concern |
| Kota et al., 2009 | Sci Transl Med | No retraction or concern |
| Zimber et al., 2011 | J Drugs Dermatol | No retraction or concern |
| Mendell et al., 2015 | Mol Ther | No retraction or concern |
| Chang et al., 2017 | Transgenic Res | No retraction or concern |
| Al-Zaidy et al., 2015 | J Neuromuscul Dis | No retraction or concern |
| Mendell et al., 2017 | Mol Ther | No retraction or concern |
| Greenberg, 2017 | Mol Ther | No retraction or concern |
| Glasser et al., 2018 | Muscle Nerve | No retraction or concern |
| Shen et al., 2018 | J Pharmacol Exp Ther | No retraction or concern |
| Pearsall et al., 2019 | Sci Rep | No retraction or concern |
| Reichel et al., 2019 | Drug Test Anal | No retraction or concern |
| Dağ et al., 2020 | Int Ophthalmol | No retraction or concern |
| Statland et al., 2022 | Muscle Nerve | No retraction or concern |
| Thomas et al., 2022 | Neurology | No retraction or concern |
| Mendias and Awan, 2026 | Sports Med | No retraction or concern |
Bring your questions to other researchers
Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.
Questions
What is follistatin-344?
Follistatin-344 is the 344-amino-acid form of follistatin, a protein the body makes that binds myostatin and activin. After a lead piece is cut off, the mature protein has 315 amino acids (UniProt P19883).
Is follistatin 344 effective for muscle growth?
In mice, monkeys and pigs, extra follistatin built muscle. In people, we found only gene-therapy trials in 12 people, one of them disputed, and a related drug that grew muscles without consistent gains in function. No trial tested injected follistatin protein (Mendell et al., 2015; Statland et al., 2022).
Is taking follistatin safe?
Not shown. No study has tested injected follistatin-344 for safety, 11 bodybuilders developed fluid under the retina after high-dose injections, and a lab found follistatin in only 9 of 17 vials (Dağ et al., 2020; Reichel et al., 2019).
What is the strongest peptide for muscle gain?
We don’t rank compounds. Follistatin-344 is a protein, and none of the compounds on our muscle growth page is approved for building muscle in healthy people.
How long does the follistatin cycle last?
No study tested a cycle of injected follistatin. The gene therapy was one set of injections, and ACE-083, a different drug, was injected into single muscles every 3 weeks in its trials. We don’t give schedules (Mendell et al., 2015; Thomas et al., 2022).
What is the follistatin 344 dosage?
We don’t give dosing advice. No study gave a person injected follistatin-344 protein, so no dose for it comes from a study. The gene-therapy trials counted virus particles, not micrograms (Mendell et al., 2015).
Is follistatin 344 a peptide?
No, it is a protein. The circulating form has 315 amino acids, and the FDA treats a chain of more than 40 amino acids as a protein (UniProt P19883; 21 CFR 600.3).
What do follistatin 344 before and after photos show?
They can’t show that it works. No controlled study of injected follistatin-344 exists, and a lab test found follistatin in only 9 of 17 vials sold under the name (Reichel et al., 2019).
What are the side effects of follistatin 344?
The one human report on injected follistatin-344 is a case series of 11 men with fluid under the retina. The gene-therapy trials reported no adverse effects in 6 men, and ACE-083, a different drug, caused mostly injection-site reactions (Dağ et al., 2020; Mendell et al., 2015; Thomas et al., 2022).
Is follistatin 344 the same as the gene therapy?
No. The gene therapy puts the FS344 gene into muscle with a virus, so the muscle makes the protein. A vial supplies the protein from outside, and no human study tested that (Mendell et al., 2017).
Does follistatin 344 grow hair?
We found no study of follistatin-344 for hair. One small trial used a cell-derived mix that contained follistatin and other factors (Zimber et al., 2011).
Is follistatin 344 legal?
It isn’t FDA-approved, and it is banned in sport at all times. It is a protein, not one of the short peptides the FDA has reviewed for compounding, and “research use only” vials aren’t approved for people (WADA, 2026; FDA rule, 2020).
Sources
- Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A. 2001;98(16):9306-11. PubMed 11459935
- Haidet AM, Rizo L, Handy C, Umapathi P, Eagle A, Shilling C, et al. Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc Natl Acad Sci U S A. 2008;105(11):4318-22. PubMed 18334646
- Kota J, Handy CR, Haidet AM, Montgomery CL, Eagle A, Rodino-Klapac LR, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med. 2009;1(6):6ra15. PubMed 20368179
- Chang F, Fang R, Wang M, Zhao X, Chang W, Zhang Z, et al. The transgenic expression of human follistatin-344 increases skeletal muscle mass in pigs. Transgenic Res. 2017;26(1):25-36. PubMed 27787698
- Rodino-Klapac LR, Haidet AM, Kota J, Handy C, Kaspar BK, Mendell JR. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve. 2009;39(3):283-96. PubMed 19208403
- Pearsall RS, Davies MV, Cannell M, Li J, Widrick J, Mulivor AW, et al. Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease. Sci Rep. 2019;9(1):11392. PubMed 31388039
- Mendell JR, Sahenk Z, Malik V, Gomez AM, Flanigan KM, Lowes LP, et al. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther. 2015;23(1):192-201. PubMed 25322757
- Al-Zaidy SA, Sahenk Z, Rodino-Klapac LR, Kaspar B, Mendell JR. Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy. J Neuromuscul Dis. 2015;2(3):185-192. PubMed 27858738
- Mendell JR, Sahenk Z, Al-Zaidy S, Rodino-Klapac LR, Lowes LP, Alfano LN, et al. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Mol Ther. 2017;25(4):870-879. PubMed 28279643
- Greenberg SA. Unfounded Claims of Improved Functional Outcomes Attributed to Follistatin Gene Therapy in Inclusion Body Myositis. Mol Ther. 2017;25(10):2235-2237. PubMed 28927986
- Glasser CE, Gartner MR, Wilson D, Miller B, Sherman ML, Attie KM. Locally acting ACE-083 increases muscle volume in healthy volunteers. Muscle Nerve. 2018;57(6):921-926. PubMed 29486514
- Statland JM, Campbell C, Desai U, Karam C, Díaz-Manera J, Guptill JT, et al. Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy. Muscle Nerve. 2022;66(1):50-62. PubMed 35428982
- Thomas FP, Brannagan TH 3rd, Butterfield RJ, Desai U, Habib AA, Herrmann DN, et al. Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease. Neurology. 2022;98(23):e2356-e2367. PubMed 35545446
- Zimber MP, Ziering C, Zeigler F, Hubka M, Mansbridge JN, Baumgartner M, et al. Hair regrowth following a Wnt- and follistatin containing treatment: safety and efficacy in a first-in-man phase 1 clinical trial. J Drugs Dermatol. 2011;10(11):1308-12. PubMed 22052313
- Reichel C, Gmeiner G, Thevis M. Detection of black market follistatin 344. Drug Test Anal. 2019;11(11-12):1675-1697. PubMed 31758732
- Erratum to Reichel C, Gmeiner G, Thevis M. Detection of black market follistatin 344. Drug Test Anal. 2020;12(10):1522-1533. PubMed 33460286. It corrects misaligned columns in Tables 1 and 2, which list recombinant follistatins and antibodies. Read November 13, 2026.
- Dağ U, Çağlayan M, Öncül H, Alakuş MF. Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series. Int Ophthalmol. 2020;40(11):3155-3161. PubMed 32671599
- Shen C, Iskenderian A, Lundberg D, He T, Palmieri K, Crooker R, et al. Protein Engineering on Human Recombinant Follistatin: Enhancing Pharmacokinetic Characteristics for Therapeutic Application. J Pharmacol Exp Ther. 2018;366(2):291-302. PubMed 29752426
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935. PubMed 41966639
- UniProt. P19883 (FST_HUMAN), Follistatin: signal peptide 1-29, mature chain 30-344, 38,007 Da. UniProt entry
- U.S. Food and Drug Administration. Definition of the Term “Biological Product.” Final rule, Federal Register, February 21, 2020, effective March 23, 2020; 21 CFR 600.3. Federal Register CFR text
- U.S. Food and Drug Administration. openFDA Drugs@FDA: search for follistatin, November 13, 2026: no match. openFDA
- U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. Content current as of April 22, 2026. FDA page
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A: categories, updated May 14, 2026 (searched for follistatin: not listed). FDA document
- ClinicalTrials.gov. Records NCT01519349, NCT02354781, NCT06411366, NCT07285629, NCT07443826, NCT02927080, NCT03124459 and NCT03943290, November 13, 2026. Search
- Europe PMC. Record of Greenberg SA, letter on follistatin gene therapy in inclusion body myositis, with the link to the published reply, read November 13, 2026. Europe PMC
- World Anti-Doping Agency. 2026 Prohibited List, class S4 (myostatin-binding proteins, e.g. follistatin). WADA document
- Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
- U.S. Food and Drug Administration. Global Substance Registration System: Follistatin (UNII 506IY26H2I). GSRS
Last reviewed Nov 13, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.